Philip Lowry, MD

Specialties:

Hematology
Medical Oncology
Care Provider Overall: 
5
Provider Reviews: 
94
  • Facebook logo
  • Twitter logo
  • Print Mail logo
  • Print HTML logo

View Locations

  • Clinical Details
  • Education
  • Clinical Trials
Hospital Privileges: 
  • Guthrie Robert Packer Hospital
Clinical Interests: 
  • Colorectal Cancer
  • Lung Cancer

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of Recommending Care Provider: 
5
Patients' Confidence in Care Provider: 
5
Time Care Provider Spent with Patient: 
5
Care Provider Spoke Using Clear Language: 
5
Care Provider Efforts to Include in Decisions: 
5
Care Provider's Concern for Questions and Worries: 
5
Care Provider's Explanations of Condition/Problem: 
5
Care Provider Information About Medications: 
5
Care Provider Instructions for Follow-Up Care: 
5
Care Provider's Friendliness and Courtesy: 
5
Residency: 
  • University of Virginia, Charlottesville, Va.
Certification: 
  • American Board of Internal Medicine/Hematology
  • American Board of Internal Medicine/Oncology
Education: 
  • Yale University School of Medicine, New Haven, Conn.
Fellowship: 
  • University of Virginia, Charlottesville, Va.
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG
Details (Identifier #): NCT02445391
Title: EA1131, A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG
Details (Identifier #): NCT02595944
Title: EA5142, Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG
Details (Identifier #): NCT02224781
Title: EA6134, A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Department: Oncology
Diagnosis: Genito-urinary - Prostate
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG
Details (Identifier #): NCT03419234
Title: Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02750826
Title: Alliance A011401, Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: G1Therapeutics
Details (Identifier #): NCT02514447
Title: G1T28-03, Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02927249
Title: A011502, A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: NCI
Details (Identifier #): NCT02465060
Title: MATCH TRIAL
Department: Oncology
Diagnosis: Brain
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02152982
Title: Alliance A071102, A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: MacroGenics
Details (Identifier #): NCT02492711
Title: MacroGenics SOPHIA, CP-MGAH22-04, A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02193282
Title: A081105, Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: Mirati
Details (Identifier #): NCT02219711
Title: Mirati 516-001: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02194738
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: RTOG
Details (Identifier #): NCT01013649
Title: RTOG-0848, A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: Roche
Details (Identifier #): NCT02624986
Title: BH29812, A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with idasanutlin in patients with relapsed or refractory follicular lymphoma and obinutuzumab or rituximab in combination with idasanutlin in patients with relapsed or refractory diffuse large B-cell lymphoma
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
  • Morelli PA-C, Catherine
Sponsor: SWOG
Details (Identifier #): NCT02154490
Title: Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: Roche
Details (Identifier #): NCT03135262
Title: BH39147, A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): NCT02595905
Title: S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Department: Oncology
Diagnosis: Head and Neck
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: BMS
Details (Identifier #): NCT02823574
Title: BMS CA209-714,A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN) (CheckMate 714: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 714)
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): NCT02562716
Title: S1505, A Randomized Phase II Study of Perioperative mFolfironix Versus Gemcitabine/Nab-paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: BMS
Details (Identifier #): NCT02869789
Title: BMS CA209-817, A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: BMS
Details (Identifier #): NCT03090737
Title: "An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants with Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least Once Prior Systemic Regimen": CA209-907-022
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG
Details (Identifier #): NCT02115282
Title: E2112, A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG
Details (Identifier #): NCT02201992
Title: E4512, A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Guthrie Patient: March 2018
*Dr. Lowry was very understanding about my choice of follow-up treatment.
Guthrie Patient: March 2018
excellent
Guthrie Patient: March 2018
still waiting for second opinion referral going on 2 weeks. I ask for it daily. apparently he's too busy but told me he would write one
Guthrie Patient: March 2018
this was my first visit to him - he was very understanding, explained everything, easy to talk to and ask questions - I will continue to see him
Guthrie Patient: January 2018
We had a list of questions to ask Dr. Lowry- I saved them to the end of our visit. By the time it was time to ask questions- I realized he had already provided info/answers to 3/4's of them!-we loved that. He made us feel very comfortable with discussing our serious health issues and we are very glad to have him as our oncologist. We would HIGHLY recommend him.
Guthrie Patient: January 2018
I'm so happy to have Dr. Lowry for my oncologist! I've been to doctors at Johns Hopkins and also at Columbia University Medical Center and as good as they are, I wouldn't trade Dr. Lowry for any of them. He has a positive attitude and a great bedside manner - he shows concern, but also has a sense of humor, and is very knowledgeable about treatment and options. I know he's booked solid, but he never makes me feel rushed or that he doesn't have time for my questions. He's the best!
Guthrie Patient: December 2017
I would certainly recommend this department to others.
Guthrie Patient: December 2017
Provider is always ready to listen to my concerns. He is very friendly and gives me courtesy.
Guthrie Patient: November 2017
I trust this Dr. with my life and have a great amount of respect for him.
Guthrie Patient: November 2017
excellent